Litcius/Paper detail

Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial

Tamim Niazi, Fred Saad, Steven Tisseverasinghe, Rashmi Koul, Isabelle Thibault, Peter Chung, G. Wakil, Michael Lock, Guila Delouya, Boris Bahoric, Andrew Feifer, Venkata Ramana Agnihotram, Theodoros Tsakiridis, Fabio Cury, Rafika Dahmane, Nikhilesh Patil, Scott Tyldesley

2025The Lancet Oncology21 citationsDOI

Topics & Concepts

MedicineProstate cancerSystemic therapyOpen labelOncologyRandomized controlled trialInternal medicineCastrationClinical trialCancerHormoneBreast cancerProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentRadiopharmaceutical Chemistry and Applications
Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial | Litcius